TARS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
173.9M
+7.3%
162.1M
+6.8%
151.7M
+27.8%
118.7M
+15.6%
102.7M
Cost of Revenue
12.1M
+28.9%
9.4M
-14.0%
10.9M
+31.5%
8.3M
+33.2%
6.2M
Gross Profit
161.8M
+6.0%
152.7M
+8.5%
140.7M
+27.5%
110.4M
+14.5%
96.4M
Operating Expenses
181.7M
+14.4%
158.8M
+6.8%
148.7M
+19.1%
124.9M
+5.3%
118.6M
R&D
31.0M
+38.7%
22.4M
+23.9%
18.0M
+10.8%
16.3M
+4.4%
15.6M
SG&A
150.7M
+10.5%
136.4M
+4.4%
130.7M
+20.3%
108.6M
+5.5%
103.0M
Operating Income
-19908000
-225.2%
-6122000
+23.2%
-7976000
+45.1%
-14529000
+34.5%
-22184000
EBITDA
-18059000
-176.4%
-6534000
+49.8%
-13015000
+7.5%
-14069000
+31.1%
-20417000
Net Income
-18551000
-166.3%
-6967000
+16.8%
-8373000
+33.5%
-12585000
+38.1%
-20340000
EPS (Basic)
$-0.43
-168.8%
$-0.16
+15.8%
$-0.19
+36.7%
$-0.30
+37.5%
$-0.48
EPS (Diluted)
$-0.43
-168.8%
$-0.16
+15.8%
$-0.19
+36.7%
$-0.30
+37.5%
$-0.48
Shares (Diluted)
43.4M
+1.0%
43.0M
+0.3%
42.8M
+0.5%
42.6M
+0.6%
42.4M
Tarsus Pharmaceuticals (TARS) โ€” Financials